ALT与AST比值预测慢性丙型肝炎患者肝脂肪变性的可行性分析

张秀丽

doi:10.3969/j.issn.1001-5256.2017.06.016

ALT与AST比值预测慢性丙型肝炎患者肝脂肪变性的可行性分析

DOI: 10.3969/j.issn.1001-5256.2017.06.016

张秀丽

南阳市第一人民医院检验科

详细信息

中图分类号: R512.63
计量
- 文章访问数: 2802
- HTML全文浏览量: 46
- PDF下载量: 493
- 被引次数: 0
出版历程
- 收稿日期: 2016-12-26
- 出版日期: 2017-06-20

Feasibility of alanine aminotransferase/aspartate aminotransferase ratio in predicting hepatic steatosis in chronic hepatitis C patients

Zhang XiuLi

Department of Clinical Laboratory, The First People's Hospital of Nanyang

摘要

摘要: 目的评价ALT/AST值预测慢性丙型肝炎（CHC）患者肝脂肪变性程度的可行性。方法选择2012年5月-2016年6月就诊于南阳市第一人民医院的CHC患者231例,其中非酒精性脂肪性肝病（NAFLD）患者105例（45.45%）,非NAFLD患者126例（54.55%）;同时根据B超评分将NAFLD组分为轻中度（12分）脂肪变性组（n=67）和重度（3分）脂肪变性组（n=38）。比较NAFLD组和非NAFLD组人口学及肌酐、空腹血糖、ALT、AST、ALT/AST、GGT、尿酸、LDL、HDL、CHO、TG等病情资料,筛选CHC合并NAFLD的独立危险因素。符合正态分布的计量资料组间比较采用独立样本t检验;不符合正态分布的数据组间比较采用Wilcoxon秩和检验;计数资料组间比较采用χ2检验;以重度NAFLD为因变量,不同因素引入logostic回归方程筛选独立危险因素。结果NAFLD组收缩压、舒张压、空腹血糖、ALT、ALT/AST值、GGT、HDL、CHO、TG和糖尿病、高血压、代谢综合征比例高于非NAFLD组（P值均<0.05）;轻中度组收缩压、舒张压、...
- 肝炎,丙型,慢性 /
- 脂肪肝 /
- 丙氨酸转氨酶 /
- 天冬氨酸氨基转移酶类
Abstract: Objective To investigate the feasibility of alanine aminotransferase (ALT) /aspartate aminotransferase (AST) ratio in predicting the degree of hepatic steatosis in chronic hepatitis C (CHC) patients. Methods A total of 231 CHC patients who visited The First People's Hospital of Nanyang from May 2012 to June 2016 were enrolled, among whom 105 (45. 45%) had nonalcoholic fatty liver disease (NAFLD) and 126 (54. 55%) did not have NAFLD. According to the ultrasound score, the NAFLD group was divided into mild-to-moderate (1-2 points) hepatic steatosis group (n = 67) and severe (3 points) hepatic steatosis group (n = 38) . The two groups were compared in terms of demographic data and disease data including creatinine, fasting blood glucose, ALT, AST, ALT/AST ratio, γ-glutamyltransferase (GGT) , uric acid, low-density lipoprotein, high-density lipoprotein (HDL) , cholesterol (CHO) , and triglyceride (TG) to screen out independent risk factors for NAFLD in CHC patients. The independent samples t-test was used for comparison of normally distributed continuous data between groups, and the Wilcoxon rank sum test was used for comparison of non-normally distributed continuous data between groups; the chi-square test was used for comparison of categorical data between groups; with severe NAFLD as the dependent variable, different factors were introduced into the logistic regression equation to screen out independent risk factors. Results Compared with the non-NAFLD group, the NAFLD group had significantly higher systolic pressure, diastolic pressure, fasting blood glucose, ALT/AST ratio, and levels of ALT, GGT, HDL, CHO, and TG, as well as a significantly higher proportion of patients with diabetes, hypertension, or metabolic syndrome (all P < 0. 05) . Compared with the severe hepatic steatosis group, the mild-to-moderate hepatic steatosis group had significantly lower systolic pressure, diastolic pressure, fasting blood glucose, ALT/AST ratio, and levels of ALT, GGT, HDL, CHO, and TG, as well as a significantly lower proportion of patients with diabetes, hypertension, or metabolic syndrome (all P < 0. 05) . The logistic regression analysis showed that metabolic syndrome, ALT, and ALT/AST ratio were independent risk factors for NAFLD (all P < 0. 05) , and metabolic syndrome, ALT, ALT/AST ratio, and GGT were independent risk factors for severe NAFLD (all P < 0. 05) . Conclusion ALT/AST ratio is an independent risk factor for NAFLD in CHC patients and has a certain value in evaluating the degree of NAFLD.
- hepatitis C, chronic /
- fatty liver /
- alanine transaminase /
- aspartate aminotransferases

HTML全文

参考文献(19)

[1]HAJARIZADEH B, GREBELY J, DORE GJ.Epidemiology and natural history of HCV infection[J].Nat Rev Gastroenterol Hepatol, 2013, 10 (9) :553-562.

[2]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for hepatitis C:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.

[3]TARGHER G, BYRNE CD.Clinical review:nonalcoholic fatty liver disease:a novel cardiometabolic risk factor for type 2 diabetes and its complications[J].J Clin Endocrinol Metab, 2013, 98 (2) :483-495.

[4]KAWAMOTO R, KOHARA K, KUSUNOKI T, et al.Alanine aminotransferase/aspartate aminotransferase ratio is the best surrogate marker for insulin resistance in non-obese Japanese adults[J].Cardiovasc Diabetol, 2012, 1 (11) :117.

[5]ZHENG RD, LU LG, MENG JR, et al.A clinical and pathological study of nonalcoholic fatty liver disease[J].Chin J Hepatol, 2006, 14 (6) :449-452. (in Chinese) 郑瑞丹, 陆伦根, 孟家榕, 等.非酒精性脂肪性肝病临床和病理学研究[J].中华肝脏病杂志, 2006, 14 (6) :449-452.

[6]Chinese Society of Diabetes, Chinese Medical Association.Chinese guidelines for prevention and treatment of type 2 diabetes (十七) -metabolic syndrome[J].Chin Community Doct, 2012, 28 (3) :10. (in Chinese) 中华医学会糖尿病学分会.中国2型糖尿病防治指南 (十七) ——代谢综合征[J].中国社区医师, 2012, 28 (3) :10.

[7]KOTRONEN A, YKI-JRVINEN H.Fatty liver a novel component of the metabolic syndrome[J].Arterioscler Thromb Vasc Biol, 2008, 28 (1) :27-38.

[8]ADINOLFI LE, RINALDI L, GUERRERA B, et al.NAFLD and NASH in HCV infection:prevalence and significance in hepatic and extrahepatic manifestations[J].Int J Mol Sci, 2016, 17 (6) :803.

[9]LEE MH, YANG HI, LU SN, et al.Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases:a community-based long-term prospective study[J].J Infect Dis, 2012, 206 (4) :469-477.

[10]MOHAMMADI F, QORBANI M, KELISHADI R, et al.Association of cardiometabolic risk factors and hepatic enzymes in a national sample of Iranian children and adolescents:the CASPIAN-III study[J].J Pediatr Gastroenterol Nutr, 2014, 58 (4) :463-468.

[11]YAIR-SABAG S, NUSSINSON E, BEN-ASSULI O, et al.Retrospective study of the associations between hepatitis C virus infection and metabolic factors[J].World J Hepatol, 2016, 8 (30) :1269-1278.

[12]VEZOZZO DC, MENDES-CORREA MC, CUNHA-SILVA M, et al.Strong correlation by ultrasonography of hepatomegaly and the presence of co-infection in HIV/HCV cirrhotic patients[J].Braz J Infect Dis, 2013, 17 (2) :150-155.

[13]QIN G, LU L, XIAO Y, et al.A cross-sectional study of the relationship between serum liver enzymes level and the incidence of impaired fasting glucose in males and females[J].Med Sci Monit, 2014, 28 (20) :1319-1325.

[14]KONG WL, YANG YL, XU HQ, et al.Relationship between liver function and virological response in patients with chronic hepatitis C during antiviral treatment[J].J Jilin Univ:Med Edit, 2016, 42 (1) :99-103. (in Chinese) 孔文丽, 杨以良, 徐洪芹, 等.慢性丙型肝炎患者抗病毒治疗中肝功能与病毒学应答的关系[J].吉林大学学报:医学版, 2016, 42 (1) :99-103.

[15]ZHANG Y, CHENG J.Hepatitis C virus related fatty liver[J].J Clin Hepatol, 2015, 31 (7) :1034-1037. (in Chinese) 张雨, 成军.HCV相关性脂肪肝[J].临床肝胆病杂志, 2015, 31 (7) :1034-1037.

[16]KUMAR A, SHARMA A, DUSEJA A, et al.Patients with nonalcoholic fatty liver disease (NAFLD) have higher oxidative stress in comparison to chronic viral hepatitis[J].J Clin Exp Hepatol, 2013, 3 (1) :12-18.

[17]GHOURI N, PREISS D, SATTAR N.Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease:a narrative review and clinical perspective of prospective data[J].Hepatology, 2010, 52 (3) :1156-1161.

[18]LIN MS, LIN HS, CHUNG CM, et al.Serum aminotransferase ratio is independently correlated with hepatosteatosis in patients with HCV:a cross-sectional observational study[J].BMJ Open, 2015, 5 (9) :e008797.

[19]ICHINO N, OSAKABE K, SUGIMOTO K, et al.The NAFLD Index:a simple and accurate screening tool for the prediction of nonalcoholic fatty liver disease[J].Rinsho Byori, 2015, 63 (1) :32-43.

施引文献

资源附件(0)

访问统计